Nemluvio is now cleared for adults with the chronic itching condition prurigo nodularis, making it a competitor to Sanofi and Regeneron’s Dupixent.
Read more about this post on BioPharmaDive
Trending
- Druckenmiller’s Duquesne Office Expands Portfolio with Broadcom and Caris Life Sciences Investments
- UberDoc Health Technologies Unveils New Leadership Team
- NMPA 2025: A New Era of Approvals in China
- Exploring the Future of Research, Cell Therapy, and Reagent Demand
- Dengue Cases Plummet 66% in Early 2026 as Home Breeding Sites Identified
- Bicara Stock Soars 50%, Boosting Biotech Investor’s Portfolio by 29%
- Navigating the Future of Consumer-Centric Therapeutics
- Bridging the Gap: AI’s Role in Digital Health Equity
